36 related articles for article (PubMed ID: 15090718)
1. Assessment of Expression of Ki-67 in Benign and Malignant Prostatic Lesions among Sudanese Patients.
Mohamed AA; Abbas MY; Alharbi H; Babiker AY
Open Access Maced J Med Sci; 2018 Oct; 6(10):1809-1812. PubMed ID: 30455753
[TBL] [Abstract][Full Text] [Related]
2. Characterization of Notch Signalling Pathway Members in Normal Prostate, Prostatic Intraepithelial Neoplasia (PIN) and Prostatic Adenocarcinoma.
Soylu H; Acar N; Ozbey O; Unal B; Koksal IT; Bassorgun I; Ciftcioglu A; Ustunel I
Pathol Oncol Res; 2016 Jan; 22(1):87-94. PubMed ID: 26341090
[TBL] [Abstract][Full Text] [Related]
3. Effectiveness of epidural versus alternate analgesia for pain relief after radical prostatectomy and correlation with biochemical recurrence in men with prostate cancer.
Mir MC; Joseph B; Zhao R; Bolton DM; Gyomber D; Lawrentschuk N
Res Rep Urol; 2013; 5():139-45. PubMed ID: 24400245
[TBL] [Abstract][Full Text] [Related]
4. Epidemiology of prostate cancer in the Asia-Pacific region.
Baade PD; Youlden DR; Cramb SM; Dunn J; Gardiner RA
Prostate Int; 2013; 1(2):47-58. PubMed ID: 24223402
[TBL] [Abstract][Full Text] [Related]
5. Evidence of mTOR Activation by an AKT-Independent Mechanism Provides Support for the Combined Treatment of PTEN-Deficient Prostate Tumors with mTOR and AKT Inhibitors.
Zhang W; Haines BB; Efferson C; Zhu J; Ware C; Kunii K; Tammam J; Angagaw M; Hinton MC; Keilhack H; Paweletz CP; Zhang T; Winter C; Sathyanarayanan S; Cheng J; Zawel L; Fawell S; Gilliland G; Majumder PK
Transl Oncol; 2012 Dec; 5(6):422-9. PubMed ID: 23323157
[TBL] [Abstract][Full Text] [Related]
6. Castration-resistant prostate cancer: systemic therapy in 2012.
Maluf FC; Smaletz O; Herchenhorn D
Clinics (Sao Paulo); 2012; 67(4):389-94. PubMed ID: 22522765
[TBL] [Abstract][Full Text] [Related]
7. Biomarker research in prostate cancer--towards utility, not futility.
Oon SF; Pennington SR; Fitzpatrick JM; Watson RW
Nat Rev Urol; 2011 Mar; 8(3):131-8. PubMed ID: 21394176
[TBL] [Abstract][Full Text] [Related]
8. Open-label, phase I dose-escalation study of sodium selenate, a novel activator of PP2A, in patients with castration-resistant prostate cancer.
Corcoran NM; Hovens CM; Michael M; Rosenthal MA; Costello AJ
Br J Cancer; 2010 Aug; 103(4):462-8. PubMed ID: 20648008
[TBL] [Abstract][Full Text] [Related]
9. Targeting CWR22Rv1 prostate cancer cell proliferation and gene expression by combinations of the phytochemicals EGCG, genistein and quercetin.
Hsieh TC; Wu JM
Anticancer Res; 2009 Oct; 29(10):4025-32. PubMed ID: 19846946
[TBL] [Abstract][Full Text] [Related]
10. Incidence, mortality and survival patterns of prostate cancer among residents in Singapore from 1968 to 2002.
Chia SE; Tan CS; Lim GH; Sim X; Pawitan Y; Reilly M; Mohamed Ali S; Lau W; Chia KS
BMC Cancer; 2008 Dec; 8():368. PubMed ID: 19087276
[TBL] [Abstract][Full Text] [Related]
11. [Epidemiology of prostate cancer: recent results from the Epidemiological Cancer Register of the District of Münster (Germany)].
Kraywinkel K; Lehnert M; Semjonow A; Hense HW
Urologe A; 2008 Jul; 47(7):853-9. PubMed ID: 18398595
[TBL] [Abstract][Full Text] [Related]
12. Cancer mortality trends in the Umbria region of Italy 1978-2004: a joinpoint regression analysis.
Stracci F; Canosa A; Minelli L; Petrinelli AM; Cassetti T; Romagnoli C; La Rosa F
BMC Cancer; 2007 Jan; 7():10. PubMed ID: 17227578
[TBL] [Abstract][Full Text] [Related]
13. Report on trends of incidence (1970-2002) of and mortality (1952-2002) from cancer in Germany.
Becker N; Altenburg HP; Stegmaier C; Ziegler H
J Cancer Res Clin Oncol; 2007 Jan; 133(1):23-35. PubMed ID: 16896882
[TBL] [Abstract][Full Text] [Related]
14. Engineering of human coagulation factor x variants activated by prostate-specific antigen.
Völkel T; Heidtmann HH; Müller R; Kontermann RE
Mol Biotechnol; 2005 Jan; 29(1):19-30. PubMed ID: 15668516
[TBL] [Abstract][Full Text] [Related]
15. International trends in prostate-cancer mortality: the decrease is continuing and spreading.
Baade PD; Coory MD; Aitken JF
Cancer Causes Control; 2004 Apr; 15(3):237-41. PubMed ID: 15090718
[TBL] [Abstract][Full Text] [Related]
16. International trends in prostate-cancer mortality in the "PSA ERA".
Oliver SE; May MT; Gunnell D
Int J Cancer; 2001 Jun; 92(6):893-8. PubMed ID: 11351313
[TBL] [Abstract][Full Text] [Related]
17. Screening for prostate cancer: updated experience from the Tyrol study.
Horninger W; Berger A; Pelzer A; Klocker H; Oberaigner W; Schönitzer D; Severi G; Robertson C; Boyle P; Bartsch G
Can J Urol; 2005 Feb; 12 Suppl 1():7-13; discussion 92-3. PubMed ID: 15780158
[TBL] [Abstract][Full Text] [Related]
18. Recent trends in prostate cancer mortality show a continuous decrease in several countries.
Bouchardy C; Fioretta G; Rapiti E; Verkooijen HM; Rapin CH; Schmidlin F; Miralbell R; Zanetti R
Int J Cancer; 2008 Jul; 123(2):421-429. PubMed ID: 18452171
[TBL] [Abstract][Full Text] [Related]
19. Detection of prostate cancer: the impact of the European Randomized Study of Screening for Prostate Cancer (ERSPC).
Schröder FH
Can J Urol; 2005 Feb; 12 Suppl 1():2-6; discussion 92-3. PubMed ID: 15780157
[TBL] [Abstract][Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
